Among the various aspects of the present disclosure is the provision of compositions and methods for modulation of dietary and microbial exposure. The present disclosure provides for compositions and methods for treating, preventing, or reducing the likelihood of development of an allergic disorder, necrotizing enterocolitis, sepsis, or an inflammatory disease, disorder, or condition in a subject including administering an effective amount of a composition comprising an EGFR ligand.

The present invention relates, in part, to a biocompatible hydrophobic-core carrier comprising a carrier, and a plurality of hydrophobic groups covalently linked to the polymeric carrier. The hydrophobic groups are capable of dissociably linking load molecules such as therapeutic agents. The hydrophobic-core carrier may also comprise protective side chains, orienting molecules, and targeting molecules.

ECM based compositions including amniotic membrane and methods for employing same to treat cardiovascular disorders.

A therapeutic composition can include an amount of amniotic fluid having a therapeutically effective amount of at least one protein, hyaluronic acid, or both. The therapeutic composition can be substantially free of lanugo, vernix, and cells harvested with the amniotic fluid.

Compositions and methods for promoting epithelial tissue regeneration to treat an oral or oropharyngeal wound, e.g., after tonsillectomy are disclosed. In particular, the invention relates to compositions comprising heparin binding epidermal growth factor like growth factor and their use in the treatment of an oral or oropharyngeal wound, e.g., post-therapy treatment to promote epithelial tissue regeneration in wounds, e.g., wounds resulting from surgical removal of tonsil tissue during tonsillectomy procedures, such as palatal, pharyngeal or lingual tonsillectomy. Additionally, HB-EGF can also be used after an adenoidectomy, a procedure sometimes combined with a tonsillectomy, to promote healing of wounds caused by surgical removal of adenoid tissue.

The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.

The present invention relates to shear-thinning α-lactalbumin hydrogels, which have a threshold and are thixotropic, to a method for preparing same and to the use thereof.

Compositions and methods are provided for the generation or treatment of chronic tympanic membrane perforation by modulation of HB-EGF activity.

The invention relates to vesicles comprising Epidermal Growth Factor (EGF), a cationic surfactant and cholesterol or derivatives thereof. The invention also discloses a procedure for their preparation, based on compressed fluid technology (CFs). The vesicles of the invention are useful in the manufacture of drugs and cosmetics and in tissue engineering.

Disclosed are methods of inducing differentiation of stem into myogenic cells without gene manipulation and for inducing proliferation of satellite cells. The cells can be used as a source of cells for transplantation in a subject in need thereof. Also disclosed is a screening assay for screening test compounds using blastomere cultures.